Literature DB >> 15020061

Influence of the course of brain inflammation on the endogenous IL-1beta/IL-1Ra balance in the model of brain delayed-type hypersensitivity response to bacillus Calmette-Guérin in Lewis rats.

Karine Palin1, Danièle Verrier, Viviane Tridon, Jane Hurst, V Hugh Perry, Robert Dantzer, Jacques Lestage.   

Abstract

Interleukin-1beta (IL-1beta) is a key player in the pathogenesis of acute and chronic inflammatory diseases at the periphery and in the brain. Its action is regulated by interleukin-1 receptor antagonist (IL-1Ra), the specific endogenous antagonist of IL-1 receptors. The ratio between local concentrations of IL-1Ra and IL-1beta is known to influence the initiation and progression of many inflammatory and autoimmune diseases at the periphery. In order to determine whether this is also the case in the brain, brain and plasma concentrations of IL-1beta and IL-1Ra were measured by ELISA in a model of chronic brain inflammation in Lewis rats, the hippocampal delayed-type hypersensitivity (DTH) response to bacillus Calmette-Guérin (BCG). Brain IL-1beta increased rapidly after intracerebral (i.c.) injection of BCG and came back to baseline concentrations 1 week later, whereas IL-1Ra increased gradually over time and remained elevated during the last 2 weeks post-BCG intracerebral injection. Following peripheral BCG challenge, brain IL-1beta increased at the site of the brain BCG and peaked 12 days later before decreasing on day 16 post-challenge. Brain IL-1Ra remained elevated during the first days post-challenge and then decreased from the 12th day post-challenge. The same temporal variations were observed in the plasma concentrations of IL-1beta and IL-1Ra. The increase in the IL-1beta/IL-1Ra ratio that was apparent from day 3 to day 12 post-challenge might be correlated with the invasion of peripheral inflammatory cells at the site of intracerebral injection. Besides showing that the course of inflammation alters the brain IL-1beta/IL-1Ra ratio, these findings point to the importance of monitoring plasma IL-1beta/IL-1Ra ratio to predict the course of brain inflammation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15020061     DOI: 10.1016/j.jneuroim.2003.12.005

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  5 in total

1.  The effects of moderate exercise and overtraining on learning and memory, hippocampal inflammatory cytokine levels, and brain oxidative stress markers in rats.

Authors:  Zahra Jahangiri; Zahra Gholamnezhad; Mahmoud Hosseini; Farimah Beheshti; Narges Kasraie
Journal:  J Physiol Sci       Date:  2019-10-22       Impact factor: 2.781

Review 2.  Mutations of complement factor I and potential mechanisms of neuroinflammation in acute hemorrhagic leukoencephalitis.

Authors:  Lori Broderick; Chhavi Gandhi; James L Mueller; Christopher D Putnam; Katayoon Shayan; Patricia C Giclas; Karin S Peterson; Seema S Aceves; Robert M Sheets; Bradley M Peterson; Robert O Newbury; Hal M Hoffman; John F Bastian
Journal:  J Clin Immunol       Date:  2012-08-29       Impact factor: 8.317

3.  Ischemic preconditioning-induced neuroprotection is associated with differential expression of IL-1beta and IL-1 receptor antagonist in the ischemic cortex.

Authors:  Jin A Shin; Eun-Mi Park; Ji-Seung Choi; Sun-Mi Seo; Jihee Lee Kang; Kyung-Eun Lee; Sunghee Cho
Journal:  J Neuroimmunol       Date:  2009-07-09       Impact factor: 3.478

4.  Toll-like receptor 4/nuclear factor-κB signaling pathway is involved in ACTG-toxin H-mediated anti-inflammatory effect.

Authors:  Xinying Yang; Guojian Zhang; Xuelian Tang; Jieying Jiao; Sung Yeon Kim; Joo Young Lee; Tianjiao Zhu; Dehai Li; Yong Gab Yun; Qianqun Gu; Hyun Park
Journal:  Mol Cell Biochem       Date:  2012-11-09       Impact factor: 3.396

5.  Interleukin-1β and interleukin-1 receptor antagonist appear in grey matter additionally to white matter lesions during experimental multiple sclerosis.

Authors:  Marloes Prins; Charlotta Eriksson; Anne Wierinckx; John G J M Bol; Rob Binnekade; Fred J H Tilders; Anne-Marie Van Dam
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.